These findings suggest that targeting the PDGF/PDGFR axis has potential in the treatment of IPF; however, clinical trials with imatinib for patients with IPF failed to show any anti-fibrotic effects [8]. Here, PDGFRB is linked to idiopathic pulmonary fibrosis.